UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Oragenics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

684023302

(CUSIP Number)

March 25, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

a.                   ☐ Rule 13d-1(b)

b.                   ☒ Rule 13d-1(c)

c.                   ☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

Item 1.

Item 2.

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

(i)       Immediately following the consummation of the underwritten public offering by the Issuer on March 25, 2019 (the “Offering”) (as disclosed in the Form 424B5 prospectus filed by the Issuer with the Securities and Exchange Commission on March 22, 2019), each of the Reporting Persons may have been deemed to have beneficial ownership of 4,747,938 shares of Common Stock, which consisted of (i) 3,333,333 shares of Common Stock held by Intracoastal and (ii) 1,414,605 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 29,445,635 shares of Common Stock outstanding as of March 19, 2019 as reported by the Issuer, plus (2) 16,666,668 shares of Common Stock shares of Common Stock that were issued at the closing of the Offering and (3) 1,414,605 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 252,062 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, and (II) 1,666,667 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 6,666,667 shares of Common Stock.

(ii)       As of the close of business on March 29, 2019, each of the Reporting Persons may have been deemed to have beneficial ownership of 3,858,977 shares of Common Stock, which consisted of (i) 525,643 shares of Common Stock held by Intracoastal, (ii) 1,666,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (iii) 1,666,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represented beneficial ownership of approximately 7.8% of the Common Stock, based on (1) 29,445,635 shares of Common Stock outstanding as of March 19, 2019 as reported by the Issuer, plus (2) 16,666,668 shares of Common Stock shares of Common Stock that were issued at the closing of the Offering, (3) 1,666,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (4) 1,666,667 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Exhibit 1

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.